In March , I penned an article highlighting Tarsus Pharmaceuticals, Inc. ( TARS ) as a Buy due to rapid commercialization of Xdemvy following FDA approval in July 2023 . Since, the stock has appreciated fromBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-fou ...